Alcon delivered its Q2 results on August 11 and the market answered with its clearest vote of confidence in months — the stock surged 6.5% on the day and is now up nearly 7% on the week to CHF 61.06, reversing a substantial portion of the damage done by May's brutal 13% post-earnings drop.
The earnings reaction is the story this week, and the contrast with May is striking. Last quarter's print sent the stock down 13.6% in a single session and a further 15% over five days. This time the directional move flipped hard. The shares had already recovered about 12% over the past month heading into the release, so bulls had been rebuilding ahead of the print. The question now is whether this week's move represents a genuine re-rating or simply a relief rally on a beaten-down name.
The lending market offers little friction in either direction. Borrow availability is extraordinarily loose — roughly 1,188% of current short interest is available to lend, meaning for every share currently borrowed, nearly twelve more sit idle in the pool. That figure has actually tightened from above 2,000% in early July, reflecting a modest uptick in borrow demand as the stock has moved. Cost to borrow has crept up about 15% over the past month to 1.10%, but remains firmly in the low single digits in absolute terms. Short interest as a percentage of free float is minimal, and the ORTEX short score of 33 sits comfortably in the middle of the universe — there is no meaningful short-side pressure here, and no squeeze dynamic to factor in.
Valuation has re-rated alongside the price. The P/E multiple has expanded roughly 1.4 turns over the past 30 days, and EV/EBITDA has moved up by about 0.3 turns over the same period. Forward EPS momentum supports some of that re-rating — the 12-month forward EPS year-on-year growth factor ranks in the 81st percentile of the universe, and the 90-day EPS momentum score sits at 68. The dividend yield factor ranks in the 99th percentile, though the last declared dividend dates to 2022, so the score likely reflects yield relative to peers rather than an active payout cycle. Analyst consensus data is too stale to be meaningful — the most recent recorded changes are more than three years old, and any historic price targets should be disregarded entirely.
Among peers, the week's moves were broadly positive but Alcon stood out. TMDX gained nearly 11% on the week, making it the only correlated peer to match Alcon's momentum. OPTOMED added 7.5%. GMED and SN. were more muted at roughly 4.5% and slightly negative respectively, while ATEC was the notable laggard, down nearly 9.5% on the week. Alcon's outperformance relative to ATEC and SN. suggests the post-earnings bid was stock-specific rather than a broad sector tailwind.
The next scheduled results are in November, leaving the stock to trade on its own momentum through the autumn. Whether this week's reaction marks a durable re-rating or a fading relief bounce is the question the coming weeks will begin to answer.
See the live data behind this article on ORTEX.
Open ALC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
